Nirmatrelvir/ritonavir (Paxlovid) failed to shorten COVID-19 symptom duration among people at standard risk for severe COVID-19 and among vaccinated people with at least one risk factor for severe ...

A 15-day course of the antiviral nirmatrelvir-ritonavir (Paxlovid) didn't improve symptoms of long COVID, according to a randomized controlled trial that was stopped early for lack of efficacy. The ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Anticoagulation and/or antiplatelet therapy with a variety of agents does not prevent acute ...

Initial trials of low-dose lithium failed to improve long COVID symptoms, but new findings suggest higher doses could offer hope for patients suffering from fatigue and cognitive impairment. Study: ...

Since its emergence at the end of 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, has infected almost 700 million individuals and claimed ...

A 15-day course of Pfizer's COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according to a study by Stanford University researchers. Currently, there are no proven ...

SIOUX FALLS, S.D. (KELO) – A bill that would have required COVID-19 vaccine disclosure during blood donations and allowed people receiving donations to request unvaccinated blood, was shot down in ...

A malaria drug President Donald Trump took to try to prevent COVID-19 proved ineffective for that in the first large, high-quality study to test it in health workers and others closely exposed to ...

Between 1998 and 2003, the budget of the National Institutes of Health was doubled. This was an extraordinary enterprise after the multiyear, post-Cold War decline in defense spending and at a time ...